Valeant versus Allergan

Allergan Salix talks trigger threats of lawsuit by William Ackman

Published: 10:42, September 23, 2014

If Allergan Inc. and Salix Pharmaceuticals Inc. go ahead with an acquisition deal, billionaire William Ackman said on Tuesday he would sue the Botox maker for bypassing its shareholders.

Pershing Square owns 9.72% of Allergan, making it the company’s largest shareholder.

It is still early days. We cannot even be certain whether Salix and Allergan have talked about terms, and a deal if there is one, is still a long way off. Several Wall Street reporters are saying, however, that negotiations are at an advanced stage.

If the two drugmakers do make progress, it would be a mighty blow for Mr. Ackman’s Pershing Square Management’s and Valeant Pharmaceuticals’ six-month struggle to acquire Allergan.

Mr. Ackman wrote a letter to Allergan’s Board of Directors. Regarding the talks with Salix, he wrote:

“This action would directly contradict your repeated published statements that: ‘While Allergan does not believe that Valeant’s offer provides compelling value relative to the alternatives available to the company, the Allergan board of directors fully supports the right of shareholders to vote on the value proposition offered by Valeant at the appropriate time.’”

A deal with no shareholder approval?

People familiar with the matter say Salix and Allergan have talked about an all-cash proposal for all of Salix’ shares, which would expire before December 18th, when Allergan’s shareholders have a special meeting. In other words, it would go ahead without shareholders’ support.

Mr. Ackman wrote:

“By undertaking an acquisition without a shareholder vote, with the purpose and desired effect of frustrating a Valeant transaction, you are breaching your commitment that shareholders would have a vote on the value proposition offered by Valeant. We do not believe you can lawfully undertake such a transaction, particularly given your failure to engage with Valeant. If you take such action we will immediately bring litigation against you (and any counterparty that aids and abets you) for breach of fiduciary duty.”

Allergan, which has a cash fund exceeding $14 billion, may have to pay up to $10 billion for Salix. If it does, the new entity would be far too big and complicated for Valeant to consider buying.

Salix Pharmaceuticals Inc., based in North Carolina, specializes in making and marketing gastrointestinal medications.

The Valeant-Allergan *hostile takeover saga is a lawyer’s heaven. In August, Allergan said it was suing Mr. Ackman and Pershing Square for insider trading as well as “other fraudulent practices.” The Botox maker also said the they had not revealed legally-required information during the lead up to Valeant’s hostile bid.

* A hostile takeover attempt occurs when the target company’s board is against the acquisition.

Pershing Square has spent the last two months threatening to sue Allergan. The Botox maker describes the threats as acts of desperation.

Christian Nordqvist Avatar

Other News

What virtual shopping tools can change before and after a purchase

Nov 19, 2026

Game-like loyalty features drew more engagement in an online grocery study

Nov 18, 2026

A delivery cue helped more shoppers move to the next checkout step

Nov 18, 2026

Small changes in a store can bring promotions back to repeat customers’ attention

Nov 18, 2026

Some sellers accept less when a buyer shares an item’s heritage

Nov 18, 2026

Changing a marketplace trust badge can change what sellers prioritize

Nov 18, 2026

Referred customers may bring in more customers of their own

Nov 18, 2026

An extra option can make an attractive menu less appealing, experiments find

Nov 17, 2026

Adding similar choices can change which products look like the middle option

Nov 17, 2026

World Bank plans e-commerce pilot for small firms in three West African countries

Nov 17, 2026

Contextual ads were the most common targeting method among EU online advertisers

Nov 17, 2026

People treat the same money differently across spending categories, study finds

Nov 17, 2026

Small-business loan applications can stall before they are formally submitted

Nov 17, 2026

Describing the parts of an experience can change how much people enjoy it

Nov 16, 2026

A prize can feel different when customers know they might have received less

Nov 16, 2026

Frequent rating requests can change how customers experience a service

Nov 16, 2026

How a business handles customer data can shape its relationship with buyers

Nov 16, 2026

Trying a customized product can shape what shoppers choose later

Nov 16, 2026

Why the way unit prices are shown can change how shoppers judge a deal

Nov 16, 2026

Why the weather can affect ratings of cold-weather gear

Nov 15, 2026